Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. (ALDX): 10 pipeline candidates · ~38 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
38.4 months
D/E 0.58 · 0% dilution
Lead: Phase 3
10 candidates
N/A
3 buys · 0 sells (180d)
A transparent, data-derived signal for Aldeyra Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$106.5M
Cash
$65.0M
Quarterly Burn
$5.1M
Runway
38.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| ADX-2191 | Phase 2 |
| ADX-246 | Phase 2 |
| ADX-248 | Phase 2 |
| ADX-629 | Phase 2 |
| ADX-631 | Phase 2 |
| ADX-743 | Preclinical |
| filing | — |
| reproxalap | Phase 3 |
| reproxalap by the pdufa date of april 2 | — |
| vehicle | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
123
Total value held
$57.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,727,484 | $8.0M |
| blackrock, inc. | 3,763,887 | $6.4M |
| aqr capital management llc | 2,829,875 | $4.8M |
| kingdon capital management, l.l.c. | 2,152,315 | $3.6M |
| 683 capital management, llc | 1,500,000 | $2.5M |
| d. e. shaw & co., inc. | 1,403,990 | $2.4M |
| geode capital management, llc | 1,251,652 | $2.1M |
| ardsley advisory partners lp | 1,250,000 | $2.1M |
| jane street group, llc | 1,140,991 | $1.9M |
| state street corp | 1,124,710 | $1.9M |
Showing top 10 of 123 institutional holders of Aldeyra Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Aldeyra Therapeutics, Inc.'s pipeline?
Aldeyra Therapeutics, Inc. (ALDX) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aldeyra Therapeutics, Inc.'s lead drug candidate?
Aldeyra Therapeutics, Inc.'s most advanced tracked candidate is ADX-2191 (Phase 2) for primary vitreoretinal lymphoma and retinitis pigmentosa.
What is Aldeyra Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aldeyra Therapeutics, Inc. has approximately 38.4 months of cash runway.
What is Aldeyra Therapeutics, Inc.'s market capitalization?
Aldeyra Therapeutics, Inc.'s market capitalization is approximately $106.5M.
Who is the CEO of Aldeyra Therapeutics, Inc.?
Dr. Todd C. Brady M.D., Ph.D. is the chief executive officer of Aldeyra Therapeutics, Inc. (ALDX).
Get the full picture on Aldeyra Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.